Study S002067

A Phase 4, Multicenter, Multi-Country, Open-Label, Single-Arm Study to Investigate the Effectiveness and Safety of Tirzepatide Once Weekly in Adult Participants With Type 2 Diabetes During Ramadan

ClinicalTrials.gov record

Registration

Registration: NCT06635057
Acronym: T-RAM
Study type: INTERVENTIONAL
Phase: PHASE4
Masking: NONE
Status: COMPLETED
Enrollment: 166
Start: 2024-10-11
Primary completion: 2026-04-15
Lead sponsor: Eli Lilly and Company
Conditions: Type 2 Diabetes
Interventions: DRUG:Tirzepatide
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:I8F-MC-GPIY

Registered primary outcomes

Change from Baseline in Hemoglobin A1c (HbA1c) [Baseline (20 to 8 weeks Before Ramadan), Week 4-8 from Start of Ramadan (SoR)]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.